Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study
Status:
Active, not recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
This rollover study will provide continuing availability to tazemetostat as a single agent to
subjects who have completed their participation in an antecedent tazemetostat study (either
with monotherapy or combination therapy).